Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial.
Alireza RamandiJacob GeorgeShahin MeratElham JafariMaryam SharafkhahAmir Reza RadmardAlireza Nateghi BaygiAlireza DelavariZahra MohammadiHossein PoustchiReza MalekzadehPublished in: Hepatology international (2023)
Major cardiovascular events are prevented in MAFLD patients who consume the Polypill. MAFLD patients benefit from the Polypill more than the general population.